At ASH 2025, researchers from Shenzhen University General Hospital reported updated Phase I/II data showing CD19/CD20 dual-target CAR-T therapy achieved a 77% ORR and durable responses with controllable safety in relapsed/refractory B-cell lymphoma.
On November 3, new clinical data were reported for a universal CD19/CD20-targeted CAR-T cell therapy (CT1190B) in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL), demonstrating promising efficacy and manageable safety.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.